Danish Pharma Stock News

In early February 2026, Novo Nordisk reported full-year 2025 results showing higher annual sales and earnings, proposed a DKK 11.70 total dividend per share for 2025, authorized a DKK 15,000 million buyback, and released positive phase 3 REIMAGINE 2 data for its CagriSema combination in type 2 diabetes. At the same time, Novo Nordisk moved to protect its GLP-1 franchise by suing Hims & Hers over compounded obesity drugs and preparing new Wegovy vial formats, highlighting how intellectual...

If you are wondering whether Novozymes is priced attractively or looks fully valued right now, this article will walk through the key numbers that matter. With the share price at DKK 400.0, recent returns have been mixed, including a 4.4% gain over the last 7 days, a 5.3% decline over 30 days, a 0.8% gain year to date, a 1.8% decline over 1 year, and gains of 21.9% and 11.5% across 3 and 5 years respectively. Recent news coverage around Novozymes has mainly focused on its position as a major...

DSV (CPSE:DSV) has drawn fresh attention after releasing its full year 2025 results, along with new 2026 EBIT guidance that includes expected synergies from the Schenker integration and a proposed ordinary dividend for 2025. See our latest analysis for DSV. At a share price of DKK 1,690.0, DSV has pulled back with a 1 day share price return of 0.73% decline and a 7 day share price return of 9.91% decline, even though the 90 day share price return of 19.65% and 1 year total shareholder return...

Key Insights The considerable ownership by individual investors in cBrain indicates that they collectively have a...

A.P. Møller - Mærsk (CPSE:MAERSK B) has opened a major ground freight hub in Southern California. The new facility is intended to speed up regional deliveries and strengthen Maersk's North American logistics network. The hub focuses on improving service reliability and supply chain efficiency for customers. This development is expected to support faster turnaround times and broader distribution capabilities across the region. A.P. Møller - Mærsk, traded as CPSE:MAERSK B, is known primarily...

Key Insights Lån & Spar Bank's significant retail investors ownership suggests that the key decisions are influenced by...

Gyldendal A/S' ( CPH:GYLD B ) strong earnings report was rewarded with a positive stock price move. We have done some...

Per Aarsleff Holding (CPH:PAAL B) has had a great run on the share market with its stock up by a significant 22% over...

The board of SJF Bank A/S ( CPH:SPKSJF ) has announced that it will be increasing its dividend by 10% on the 10th of...

Context for Bavarian Nordic’s Recent Share Performance Bavarian Nordic (CPSE:BAVA) has drawn investor attention after recent share price moves, with a 1 day return of about a 0.6% decline and a past month return near a 4.5% decline setting the near term context. See our latest analysis for Bavarian Nordic. Stepping back from the recent weakness, Bavarian Nordic’s 90 day share price return of 8.84% and 1 year total shareholder return of 12.22% suggest momentum has been improving despite a...

What Novo Nordisk’s Recent Returns Signal for Investors Novo Nordisk (CPSE:NOVO B) has drawn attention after a recent mix of returns, including a 1.7% gain over the past day, a 5.5% rise across the past week, and a decline of about 17.6% over the past month. See our latest analysis for Novo Nordisk. Those mixed short term share price moves sit against a year to date share price return of 5.6% decline and a 1 year total shareholder return of 42.5% decline. This suggests momentum has cooled...

If you are wondering whether ALK-Abelló is attractively priced right now, you are not alone, and this article will walk you through the key valuation angles that matter for long term investors. The stock last closed at kr214.40, after a relatively flat 7 day return of 0.1%, a 6.0% decline over the past 30 days, and longer term returns of 35.5% over 1 year, 93.5% over 3 years, and 61.6% over 5 years that may have changed how investors see its risk and reward profile. Recent coverage of...

Why Danske Bank (CPSE:DANSKE) is on investors’ radar Danske Bank (CPSE:DANSKE) has drawn fresh attention after a strong 1 year total return of 56.1%, prompting investors to reassess how its current valuation lines up with recent business performance and fundamentals. See our latest analysis for Danske Bank. At a share price of DKK337.8, Danske Bank has delivered a 5.8% 1 month share price return, while its 1 year total shareholder return of 56.1% and very large 5 year total shareholder return...

Novo Nordisk has secured a legal win after telehealth rival Hims & Hers dropped plans to sell a copycat oral semaglutide product. The move follows Novo Nordisk filing a lawsuit to protect patents around its key weight loss drug, including the Wegovy pill. US regulators have signaled tougher oversight of unauthorized compounded GLP-1 drugs, reinforcing the company’s intellectual property position. For investors watching CPSE:NOVO B, this legal outcome comes at a time when the stock has seen...

Novozymes is being highlighted as a key player in the rapid global build out of synthetic biology and bioprocessing capacity. Large government programs in several major economies are directing multi billion dollar funding into this sector. These initiatives are expected to influence how Novozymes is positioned for future projects and collaborations. The focus on synthetic biology puts CPSE:NSIS B in the middle of a sector that is currently attracting heavy policy attention and capital...

Stock moves and recent performance A.P. Møller - Mærsk (CPSE:MAERSK B) has been under pressure recently, with the share price down about 0.1% on the day, 4.8% over the past week, and 6.5% over the past month. See our latest analysis for A.P. Møller - Mærsk. Stepping back from the recent weakness, A.P. Møller - Mærsk’s short-term share price returns have softened, while the 90-day share price return of 22.18% and 1-year total shareholder return of 38.42% still point to stronger earlier...

DSV A/S' ( CPH:DSV ) recent soft profit numbers didn't appear to worry shareholders, as the stock price showed...

The market was pleased with the recent earnings report from Carlsberg A/S ( CPH:CARL B ), despite the profit numbers...

Gyldendal A/S ( CPH:GYLD B ) shares have continued their recent momentum with a 28% gain in the last month alone. The...

Rockwool A/S' ( CPH:ROCK B ) recent soft profit numbers didn't appear to worry shareholders, as the stock price showed...

Why Embla Medical hf (CPSE:EMBLA) is on investors’ radar now Embla Medical hf (CPSE:EMBLA) has attracted fresh attention after issuing 2026 earnings guidance calling for 5 to 8% organic sales growth, alongside reporting higher fourth quarter and full year 2025 sales, net income, and earnings per share. See our latest analysis for Embla Medical hf. The earnings beat and fresh 2026 guidance have come after a softer share price patch, with a 30 day share price return showing a 4.9% decline and a...

Pandora’s higher dividend proposal and steady EPS catch investors’ attention Pandora (CPSE:PNDORA) shares have been in focus after the jewellery group paired its 2025 earnings report with a higher proposed dividend and solid basic and diluted earnings per share figures. See our latest analysis for Pandora. Despite the upbeat 2025 earnings and higher proposed dividend, Pandora’s recent share price performance has been weak, with a 90 day share price return of 30.55% decline and a 1 year total...

Regulatory milestone and why it matters for ALK-Abelló ALK-Abelló (CPSE:ALK B) is in focus after the European Medicines Agency’s CHMP issued a positive opinion supporting an extension of EURneffy’s marketing authorisation to include a 1 mg nasal adrenaline spray for children. This regulatory step, if converted into full European Commission approval, could broaden EURneffy’s eligible patient group across the EU, Iceland, Liechtenstein and Norway, giving investors another reference point when...

Genmab (CPSE:GMAB) is back on investors’ radar after recent share price swings, with the stock showing a 0.3% move over the past day but negative returns over the past month and past 3 months. See our latest analysis for Genmab. That recent 7 day share price return of 7.6% decline and 30 day share price return of 11.2% decline sit against a 1 year total shareholder return of 41.2%. This suggests near term momentum has cooled after a strong longer term run. If Genmab’s moves have you thinking...